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Abstract 
Introduction: Nosocomial pneumonia remains an important cause of mortality and morbidity worldwide. Surveillance programs play an 
important role in the identification of common etiologic agents and local patterns of antimicrobial resistance. 
Methodology: In this study we determined the frequency and antimicrobial susceptibility of pathogens isolated from patients with 
nosocomial pneumonia during 2009 to 2011. 
Results: A total of 642 bacteria were isolated from 516 suspected samples. Acinetobacter baumannii (21.1%, n = 136), was the commonest 
isolated pathogen followed by Pseudomonas aeruginosa (17.4%, n = 112), Staphylococcus aureus (15.8%, n = 102) and enterococci (8.4% n 
= 54). The most effective therapeutic agents against A. baumannii were polymyxin B (95.5% susceptible), ceftriaxone/tazobactam (72% 
susceptible) and levofloxacin (52.9% susceptible). Polymixin B (89.2% susceptible), ceftriaxone/tazobactam (89.2% susceptible) and 
piperacillin-tazobactam (80.3% susceptible) were found to be the most active agents against P. aeruginosa. Extended-spectrum beta-
lactamases were detected among isolates of K. pneumoniae (45.4%) and E. coli (20.3%). Overall, the prevalence of methicillin-resistant S. 
aureus and vancomycin resistant enterococci were 80.4% and 40.7% respectively. Linezolid was found to be the most active antibiotic 
against these pathogens. The etiology of 50% of the nosocomial infection cases was polymicrobial. 
Conclusions:  The combination of ceftriaxone/tazobactam seems to be beneficial agent against multidrug-resistant Gram-negative bacilli 
isolated form respiratory tract infections. The results of our study can be used for guiding appropriate empiric therapy in this geographic 
region. 
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Introduction 
Nosocomial pneumonia (NP) is the second most 
common nosocomial infection and the leading cause 
of death attributed to hospital-acquired infections [1]. 
It accounts for 15% of all nosocomial infections. 
Because of its association with increased mortality 
rates, prolonged hospital stays and high costs of 
hospital care, NP is a major infection control problem 
[2]. It has been estimated that between one third to one 
half of all NP deaths stem from infection [1]. 
Approximately two thirds of these infections are 
caused by Gram-negative bacilli and in particular by 
Pseudomonas aeruginosa and Acinetobacter species, 
which cause higher mortality rates related to NP [1]. 
Importantly, Gram-positive cocci infections are on the 
rise and Staphylococcus aureus is most frequently 
associated with NP [3]. NP should be considered a 
microbiological emergency and delaying prompt 
treatment gives rise to adverse outcomes. It is 
therefore vital to initiate appropriate empiric therapy 
until a microbiological diagnosis is established. 
Awareness of local prevalence of causative 
microorganisms and drug susceptibility patterns is 
critical for the proper formulation of initial empiric 
therapy prescription of antibiotics [2]. Limited data 
concerning the etiological agents of NP and their 
resistance to antibiotics was available in Iran. 
Therefore, the objective of the present study was to 
investigate the prevalence and antimicrobial resistance 
patterns of bacterial pathogens isolated from patients 
with NP over a period of three years (2009 to 2011) in 
Tehran hospitals. 
 
Methodology 
This study was conducted in the Microbiology 
Department of Tehran University of Medical Sciences 
during 2009 to 2011. A total of 516 clinically 
suspected specimens including bronchoalveolar lavage 
(BAL) (n = 121), mini BAL (n = 232), tracheal 
aspirates (n = 99), and sputum (n = 64) were collected 
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from patients with NP from three main teaching 
hospitals in Tehran. NP was defined based on the 
Infectious Diseases Society of America (IDSA) and 
the American Thoracic Society (ATS)/guidelines [4]. 
The cut-off value for different types of laboratory 
specimens considered clinically significant in 
quantitative cultures was 104 cfu/ml for BAL, 103−104 
cfu/ml for mini BAL, 105 cfu/ml for undiluted tracheal 
secretions, and 105 cfu/ml for sputum [5]. 
All specimens were cultured directly on blood 
agar, chocolate agar, and eosin methylene blue agar or 
MacConkey agar and incubated overnight at 37°C 
aerobically. Also, 0.5 to 1 mL of the specimen was 
inoculated into a tube of enriched thioglycolate broth. 
Identification of bacterial isolates was based on Gram 
staining, colonial morphology, and biochemical 
properties [6]. 
Antimicrobial susceptibility tests were performed 
on Mueller-Hinton agar using the standard disk 
diffusion method according to the guidelines 
recommended by Clinical and Laboratory Standards 
Institute (CLSI) [7]. Antibiotics tested were 
amoxycillin/clavulanic acid, polymixin B, amikacin, 
gentamicin, tobramycin, imipenem, levofloxacin, 
cefepime, ceftriaxone, ceftriaxone/tazobactam, 
ceftazidime, ciprofloxacin, azithromycin, oxacillin, 
linezolid, vancomycin and piperacillin/tazobactam 
(Hi-Media, Mumbai, India). Acinetobacter baumannii 
(NCTC 19606), Pseudomonas aeruginosa (ATCC 
27853), Stenotrophomonas maltophilia (NCTC 
10257), Klebsiella pneumoniae (NCTC 5056), 
Escherichia coli (ATCC 25922), Staphylococcus 
aureus (ATCC 29213), Streptococcus pneumoniae 
(NCTC 11910), Enterococcus faecalis (ATCC 29212) 
and Enterococcus faecium (D 366) were used as 
control strains. Detection of methicillin-resistant S. 
aureus (MRSA) was performed on Mueller-Hinton 
agar containing NaCl (4%w/v). According to CLSI 
criteria, isolates of E. coli and K. pneumoniae  which 
showed an enhanced zone of inhibition toward 
ceftazidime (30 μg ≤ 22 mm)  and/or ceftriaxone (30 
μg  ≤ 25 mm) were considered as extended-spectrum 
beta-lactamases (ESBL) producing organisms and 
were subjected for phenotypic confirmatory tests using 
the combined disk method. The zone of inhibition of 
discs containing cephalosporin with clavulanic acid 
(10 μg) was compared to the zone around a disc 
containing cephalosporin alone. A ≥ 5-mm increase in 
a zone diameter was used to indicate ESBL 
production. Statistical analyses were performed using 
the chi-square test and values of p < 0.05 were 
considered statistically significant. 
 
Results 
Of 516 clinical respiratory specimens, 81.3% (n = 
420) were positive for at least one bacterial pathogen. 
A total of 642 microorganisms were isolated and 
polymicrobial growth was observed in 50% of the 
cases. The frequency of the 10 most common 
pathogens isolated from patients with pneumonia 
hospitalized in the three teaching hospitals during the 
period of 2009, 2010, and 2011 are listed in Table 1. 
A. baumannii was the dominant organism isolated 
from patients (21.1%). It was followed by P. 
Table 1. Frequency of isolated pathogens from patients with nosocomial pneumonia during three years 
Rank Isolated bacteria 
Year  of isolation    (total number of pathogens) 
2009 (274) 
n (%) 
2010 (202) 
n (%) 
2011 (166) 
n (%) 
Total (642) 
n (%) 
1 A. baumanii 36 (13.1) 58 (28.7) 42 (25.3) 136 (21.1) 
2 P. aeruginosa 60 (21.8) 32 (15.8) 20 (12) 112 (17.4) 
3 
S. aureus  
42 (15.3) 
3                                                                                                                                          
6 (17.8) 
24 (14.4) 102 (15.8) 
4 Enterococcus sppa 32 (11.6) 16 (7.9) 6 (3.6) 54 (8.4) 
5 E. coli 22 (8) 10 (4.9) 16 (9.6) 48 (7.4) 
6 K. pneumoniae 10 (3.6) 22 (10.8) 12 (7.2) 44 (6.8) 
7 S. maltophilia 18 (6.5) 8 (3.9) 12 (7.2) 38 (5.9) 
8 Enterobacter spp b 18 (6.5) 4 (1.9) 10 (6) 32 (4.9) 
9 S. epidermidis 12 (4.3) 0 (0) 4 (2.4) 16 (2.4) 
10 S. pneumoniae 4 (1.4) 2 (0.9) 8 (4.8) 14 (2.1) 
11 Other 7 species c 20 (7.2) 14 (6.9) 12 (7.2) 46 (7.1) 
Enterococci:  E.  faecalis ( 48), E. faecium (6) 
b Enterobacter spp., E. cloacae (18), E. aerogenes (14) 
c includes Proteus spp. (6 isolates), Morganella morganii (2 isolates), Serratia marcescens (4 isolates), Alcaligenes spp. (6 isolates), 
other Streptococci (viridians: 4 isolates), non enterococcal Group D (8 isolates), Candida albicans (12 isolates), Aspergillus niger (4 
isolates) 
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aeruginosa (17.4%), S. aureus (15.8%), Enterococci 
(8.4%), and E. coli (7.4%). Overall, Gram-negative 
genera constituted 426 (66.3%) of all positive cultures, 
while Gram-positive bacteria account for 198 (30.8%) 
of the recovered pathogens.  
 
Drug susceptibility of Gram-negative bacteria 
The results of susceptibility testing for the five 
Gram-negative bacilli that most frequently cause 
pneumonia are summarized in Table 2. According to 
the antimicrobial susceptibility results of, polymixin B 
(95.5% susceptible) ceftriaxone/tazobactam (72% 
susceptible), and levofloxacin (52.9% susceptible) 
would be the best therapeutic agents against A. 
baumanii. 
Polymixin B (89.2% susceptible), 
ceftriaxone/tazobactam (89.2% susceptible) and 
piperacillin-tazobactam (80.3% susceptible) were 
found to be the most effective drugs against P. 
aeruginosa. While no significant variation in 
proportion of imipenem-resistant P. aeruginosa was 
observed during 2009 (20%, n = 12 out of 60) and 
2010 (18.75 %, n = 6/32), the resistance rate in 2011 
(60%, n = 12/20) increased significantly (p < 0.01). 
Furthermore, 70% of imipenem-resistant isolates of P. 
aeruginosa were also resistant to one or two 
fluoroquinolones. Production of ESBLs was detected 
among isolates of K. pneumoniae (n = 20, 45.4%) and 
E. coli (n = 10, 20.8%). Most of other the common 
Gram-negative bacilli demonstrated high susceptibility 
toward ceftriaxone/tazobactam and piperacillin-
tazobactam.  
 
Drug susceptibility of Gram-positive bacteria 
The results of the antimicrobial agents that were 
tested against S. auresus and enterococci are shown in 
Table 2. The frequency of MRSA was 80.4%. 
Linezolid and vancomycin (100% susceptible) were 
the most effective agents against S. aureus in this 
study. All enterococci were fully susceptible to 
linezolid, but 40.7% of them showed resistance to 
vancomycin. 
 
Discussion 
In the current study the most common pathogens 
isolated from patients with nosocomial pneumonia 
were A. baumanii followed by P. aeruginosa and S. 
aureus. In another study conducted in southern Iran, A. 
baumannii was also ranked as the first agent. 
However, S. aureus was found to be the second most 
common agent of ventilator-associated pneumonia [8]. 
A. baumannii showed high resistance to most of the 
assessed antimicrobials. In our study, 75% of the A. 
baumannii isolates were resistant to imipenem. High 
rates of resistance to imipenem (52.5%) have 
previously been described in literature from Iran [10].  
In a global study performed in 2010, out of 515 
isolates 471 (91.4%) exhibited resistance to imipenem 
[11]. The most effective compound tested against this 
pathogen was polymyxin B which could inhibit 100% 
of the isolates. Moreover, ceftriaxone/tazobactam 
showed good inhibitory effect against A. baumannii, 
suggesting this compound as a therapeutic agent 
against this pathogen. 
P. aeruginosa was the second most common 
pathogen causing pneumonia in our study. Resistance 
of this organism to imipenem increased from 20% to 
60% during the study period. Prior fluoroquinolone 
use has been identified as a risk factor for the 
emergence of imipenem-resistant P. aeruginosa 
(IRPA) [12,13]. A decrease in the permeability of the 
cellular wall in fluoroquinolone-resistant isolates of P. 
aeruginosa induces cross-resistance to carbapenems 
[12]. Out of 30 IRPA, 21 (70%) showed resistance to 
ciprofloxacin or levofloxacin, suggesting that cross-
resistance developed for imipenem due to prior use of 
fluoroquinolones (p < 0.05). Prior use of imipenem has 
been identified as another risk factor giving rise to 
infection with IRPA [13].  
Production of ESBLs was more frequently 
observed among K. pneumoniea isolates. In other 
studies reported from Iran, incidence of ESBL 
phenotypes varied from 45.2% to 67.2% for E. coli 
and 44.4% to 52% for K. pneumoniae [14]. 
Ceftriaxone/tazobactam and piperacillin/tazobactam 
were effective agents against both ESBL-producing K. 
pneumoniea and E. coli. Moreover, amikacin was also 
effective against ESBL-producing E. coli. 
In our study ceftriaxone/tazobactam was found to 
be a potent antimicrobial agent against non-fermenting 
and other prevalent Gram-negative bacilli. A 
combination of tazobactam with other penicillin 
derivatives is widely used in clinical practices. The 
efficacy of the ceftriaxone/tazobactam combination 
has been assessed in animal models and certain 
bacterial species [15,16,17,18]; however, no data is 
available on the effect of this combination against non-
fermenters. In this study we observed good inhibitory 
effects of ceftriaxone/tazobactam combination against 
non-fermenters.  
In contrast to other investigations, enterococci 
were placed among the top four pathogens causing 
nosocomial pneumonia in our study. Pneumonia 
caused by enterococci has not been previously  
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Table 2.  Drug susceptibility patterns of the most prevalent Gram-negative and Gram-positive pathogens causing pneumonia 
Antibiotic 
Disk 
content 
(μg) 
Susceptibility of Gram-negative bacteria 
% S:I:R 
A. baumanii P. aeruginosa E. coli K. pneumoniae S. maltophilia 
Imipenem 10 4.4: 20.5: 75 50: 23.2:26.7 50:29.1:20.8 43.1:36.3:20.4 26.3:47.3:26.3 
Gentamicin 10 5.9: 4.4: 88.2 21.4:5.3:73.2 50:50:0 16:34:50 0:10.5:89.4 
Ciprofloxacin 5 23.5: 8.8: 67.6 67.8:7.1: 25 70.8:0:29.1 34:6.8:59 0:0:100 
Levofloxacin 5 52.9: 26.4:20.5 46.4: 17.8: 35.7 70.8:16.6:12.5 84:0:16 63.1: 13.1:23.6 
Amikacin 30 14.7: 36.7:48.5 67.8: 16:16 75:16.6:8.3 34:15.9:50 21:34.2:44.7 
Tobramycin 10 36.7:27.9:35.2 48.2:16:35.7 50:0:50 40.9:18.1:40.9 13.1: 23.6: 63.1 
Cefepime 30 2.9: 0:97 14.2:8.9:76.7 45.8:20.8:33.3 0:18.1:81.8 0:0:100 
Ceftriaxone 30 5.8: 17.6: 76.4 17.8: 8.9 : 73.2 25:16.6:58.3 0:4.5:95.4 0:0:100 
Ceftriaxone/  
tazobactam * 
80/10 72:-:- 89.2: -:- 79.1:-:- 81.8:-:- 84.2:-:- 
Ceftazidime 30 10: 4.4: 85.2 26.7: 3.5:69.7 0:25:75 2.2:2.2:95.4 0:0:100 
Piperacillin-
tazobactam 
100/10 47:17.6: 35.2 80.3: 16: 3.5 75:8.3:16.6 72.7:27.2:0 78.9:0:21 
Amoxicillin/ 
clavulanic acid 
20/10 0:0:100 0:3.5:96.4 0:12.5:87.5 0:0:100 0:0:100 
Azithromycin 15 35.2: 14.7: 50 66:14.2: 19.6 50:50:0 59:41:0 50:26.3:23.6 
Polymyxin B 300 units 95.5:4.4:0 89.2:10.7:0 0:0:0 0:0:0 0:0:0 
 
Susceptibility of  Gram-positive bacteria 
S. aureus Enterococci 
S I R S I R 
Clindamycin 2 19.6 9.8 70.6 11.1 0 88.88 
Linezolid 30 100 0 0 100 0 0 
Ciprofloxacin 5 15.6 9.8 74.5 22.2 37 40.7 
Levofloxacin 5 66.6 9.8 23.5 59.2 25.9 14.8 
Vancomycin 30 100 0 0 48.1 11.1 40.7 
Amoxicillin/ 
clavulanic acid 
20/10 13.7 17.6 68.6 55.5 11.1 33.3 
Chloramphenicol 30 66.6 9.8 23.5 51.8 29.6 18.5 
Oxacillin 1 13.7 5.9 80.4 0 0 0 
* Isolates showing inhibitory zone > 32 mm were considered as susceptible. 
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reported from Iran. Respiratory tract infections caused 
by enterococci are exceedingly rare [19]. The 
oropharynx has been identified as a colonization route 
of enterococci in the respiratory tract [19,20]. Gastric 
colonization of enerococci has been also suggested as 
a reservoir of enterococci involved in nosocomial 
infections [20]. Selective decontamination of the 
digestive tract and oropharynx is widely used to 
prevent nosocomial pneumonia in mechanically 
ventilated patients. Administration of antimicrobial 
prophylaxis causes modification of the bacterial flora 
of such patients, giving rise to increased colonization 
with species which are intrinsically resistant to the 
antibiotics used [21], which can lead to pneumonia 
caused by microorganisms which are rarely involved 
in respiratory tract infections [21].  
 
Conclusion 
In summary, we observed a high prevalence of 
multidrug-resistant non-fermentative Gram-negative 
bacilli, MRSA, vancomycin-resistant enterococci 
(VRE), and ESBL-producing isolates. Co-ordinated 
multidisciplinary approaches are required to prevent 
and control infections caused by these antibiotic-
resistant bacteria. These measures could be achieved 
by routine culturing and susceptibility testing to detect 
MRSA, VRE and other multidrug-resistant organisms. 
Misuse or overuse of antimicrobials and long-term 
prophylaxis should be avoided and antibiotics should 
be prescribed for diagnosed infections and not for 
colonization or contamination. The results of this 
study may be helpful for administration of effective 
empiric treatment regimens and reduction of drug 
resistance in this region. 
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Haemophilus influenzae serotype e meningitis in an adult. 
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The incidence of Haemophilus influenzae type b (Hib) invasive disease has declined significantly in countries with 
routine infant Hib immunization. Accordingly, infections caused by other H. influenzae serotypes or by 
encapsulated H. influenzae strains are of growing interest. H. influenzae serotype e (Hie) is a rare cause of 
infection. Invasive Hie infections reported in adults are generally in individuals who had previous underlying 
conditions, in contrast to infections in childhood. We present the first report of Hie meningitis in Turkey. It is of 
interest that meningitis due to this organism occured as a complication of transsphenoidal hypophysectomy, which 
to our knowledge has never been documented. Further identification of H. influenzae strains isolated from patients 
with invasive disease, especially those with predisposing factors and/or who have been vaccinated, is essential. 
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